A Biologics License Application was submitted to the FDA for loncastuximab tesirine, an antibody-drug conjugate, as treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
A Biologics License Application (BLA) was submitted to the FDA for loncastuximab tesirine (Lonca), an antibody-drug conjugate, as treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).1
“The completion of our first BLA submission to the FDA is a significant milestone for ADC Therapeutics and takes us one step further in our evolution toward becoming a commercial-stage organization,” said Chris Martin, chief executive officer of ADC Therapeutics, in a statement.
The BLA was supported by results from the phase 2 LOTIS 2 study, which assessed the safety and efficacy loncastuximab tesirine in relapsed/refractory DLBCL following 2 or more prior lines of therapy.
LOTIS enrolled 145 patients who had a median of 3 prior lines of therapy (range, 2-7). The histologies associated with the study population were high-grade B-cell lymphoma with MYC and BCL2 and/or BLC6 rearrangements (11.0%), primary mediastinal B-cell lymphoma (4.1%), and transformed indolent lymphoma (17.9%). Disease was stage IV in 63.4% of the patients enrolled. Patients had a median age of 66 years (range, 23-94). DLBCL not otherwise specified was observed in 84.8% of patients. There were some patients who had received stem cell transplantation (16.6%). It was noted that 20.0% of patients were primary refractory to their most recent therapy and 56.5% were refractory.1,2
All patients in the study received a median of 3 cycles (range, 1-10) of loncastuximab tesirine.
Patients were evaluated for the primary end point of overall response rate (ORR). In addition, patients were evaluated for duration of response (DOR), complete response (CR) rate, relapsed-free survival, progression-free survival, overall survival, and the frequency and severity of adverse events (AEs), as well as serious AEs as key secondary end points.
Treatment with loncastuximab tesirine led to an ORR of 48.3% with CRs observed in 24.1% of patients.
Overall, the drug appeared tolerable. The most common treatment-emergent AEs observed in the study occurring in ≥10% were neutropenia (25.5%), thrombocytopenia (17.9%), gamma-glutamyl transferase increased (16.6%), and anemia (10.3%). Among patients who experienced neutropenia, there was also a low incidence of febrile neutropenia (3.4%).
“A critical unmet need remains for heavily pretreated patients with relapsed or refractory DLBCL, including those with a poor prognosis, those who never responded to prior therapy and those who received prior stem cell transplant,” stated Jay Feingold, MD, PhD, senior vice president and chief medical officer of ADC Therapeutics. “Based on the anti-tumor activity, durability and generally manageable tolerability Lonca has demonstrated in LOTIS 2, we believe Lonca has the potential to fill this need.”
The phase 2 multicenter, open-label, single-arm clinical trial is ongoing but no longer recruiting patients. Those enrolled were required to be at least 18 years of age with a pathologic diagnosis of DLBCL according to the 2016 World Health Organization classification. Other requirements for enrollment included relapsed/refractory disease, measurable disease, available tumor tissue, an ECOG performance status of 0 to 2, and adequate organ function.
Individuals were ineligible to enroll if they had prior treatment with loncastuximab tesirine, known history of hypersensitivity to serum human ADA, a pathologic diagnosis of Burkitt lymphoma, and had undergone prior treatment that may have interfered with the study treatment.
Currently, another study of loncastuximab tesirine (LOTIS 5, NCT04384484), which is pivotal phase 2 clinical trial in patients with relapsed/refractory DLBCL. The drug is also being evaluated in combination with ibrutinib (Imbruvica) in both patients with DLBCL and mantle cell lymphoma, in the LOTIS 3 clinical trial (NCT03684694).
References:
1. ADC Therapeutics submits Biologics License Application to the U.S. Food and Drug Administration for loncastuximab tesirine for treatment of relapsed or refractory diffuse large b-cell lymphoma. News release. September 21, 2020. Accessed September 21, 2020. https://bit.ly/2RQpm4I
2. Carlo-Stella C, Zinzani PL, Kahl B, et al. Initial results of a phase 2 study of loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory diffuse large b-cell lymphoma. EHA Library. 2020; 2 95053; S233
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More